Clinical failures: The tip of the iceberg?

Respiratory Medicine

Volumn 95, Issue SUPPL.1, 2001, Pages

  Garau, J ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

Antimicrobial agent; Bacteriological eradication; Community acquired respiratory tract infections; Pneumococcal resistance; Treatment failure

Indexed keywords

EID: 0002252199     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2001.1087     Document Type: Article

References (40)

1. Felmingham D, Grüneberg RN and the Alexander Project Group. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.
2. th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, May 28-31, 2000. Clin Infect Dis 2000; 6(Suppl. 1): 78 (Abstract WeP65).
3. th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, May 28-31, 2000. Clin Infect Dis 2000; 6(Suppl. 1): 78 (Abstract WeP65).
4. th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, May 28-31, 2000. Clin Infect Dis 2000; 6(Suppl. 1): 87 (Abstract WeP107).
5. th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, May 28-31, 2000. Clin Infect Dis 2000; 6(Suppl. 1): 87 (Abstract WeP107).
6. Wang H, Huebner R, Chen M, Klugman K. Antibiotic susceptibility patterns of Streptococcus pneumoniae in China and comparison of MICs by agar dilution and E-test methods. Antimicrob Agents Chemother 1998; 42: 2633-2636.
7. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drugresistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18: 1-9.
8. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000; 160: 1399-1408.
9. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-140.
10. Marchant CD, Carlin SA, Johnson CE, Shurin PA. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the 'Pollyanna phenomenon'. J Pediatr 1992; 120: 72-77.
11. Cohen R. The antibiotic treatment of acute otitis media and sinusitis in children. Diagn Microbiol Infect Dis 1997; 27: 35-39.
12. Jacobs MR. Increasing importance of antibioticresistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J 1996; 15: 940-943.
13. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255-259.
14. Dagan R, Abramson O, Leibovitz E, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J 1996; 15: 980-985.
15. Dagan R, Leibovitz E, Greenberg D, Yagupsky P, Fliss DM, Leiberman A. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J 1998; 17: 776-782.
16. Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in the treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44: 43-50.
17. Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19: 95-104.
18. Pallarès R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-480.
19. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1998; 29: 321-327.
20. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90: 223-229.
21. Sanchez C, Armengol R, Lite J, Mir I, Garau J. Penicillin-resistant pneumococci and community-acquired pneumonia. Lancet 1992; 339: 988.
22. Garau J, Lonks JR, Gomez L, Xercavins M, Medeiros AA. Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumoniae. 5th International Conference on Macrolide, Azalides and Streptogramins, Sevilla, Spain, January 26-28, 2000. Abstract N 709.
23. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-1011.
24. Berry V, Page R, Satterfield J, Singley C, Straub R, Woodnutt G. Comparative in vivo activity of gcmifloxacin in a rat model of infection. J Antimicrob Chemother 2000; 45(Suppl S1): 79-85.
25. Johnston NJ, De Azavedo JC, Kellner JD, Low DE. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2425-2426.
26. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40: 1817-1824.
27. Chen DK, McGeer A, Azavedo JC, Low DE for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-239.
28. Perez-Trallero E, Garcia-Arenzana JM, Jimenez JA, Peris A. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur J Clin Microbiol Infect Dis 1990; 9: 905-906.
29. Saito H, Kajita M, Shimokata K. Overwhelming pneumococcal pneumonia in a patient receiving ofloxacin for antimicrobial prophylaxis. Jpn J Med 1990; 29: 89-90.
30. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991; 325: 520-521.
31. Gordon JJ, Kaufman CA. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. Am J Med 1990; 89: 383-384.
32. Neu HC. Clinical use of the quinolones. Lancet 1987; ii: 1319-1322.
33. Kalager T, Andersen BM, Bergan T, et al. Ciprofloxacin versus tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. Scand J Infect Dis 1992; 24: 637-646.
34. Kayser FH, Novak J. In vitro activity of ciprofloxacin against Gram-positive bacteria. Am J Med 1987; 82(Suppl 4A): 33-39.
35. Bergan T, Dahloff A, Rohwedder R. Pharmacokinetics of ciprofloxacin. Infection 1988; 16(Suppl 1): S3-S13.
36. Wortman GW, Bennett SP. Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae. Clin Infect Dis 1999; 29: 1599-1600.
37. Aubier M, Verster C, Regamey C, Geslin P, Vercken J-B and the Sparfloxacin European Study Group. Oncedaily sparfloxacin versus high-dose amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clin Infect Dis 1998; 26: 1312-1320.
38. Woodnutt G, Berry V. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 29-34.
39. Woodnutt G, Berry V. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 35-40.
40. Doit C, Loukil C, Fitoussi F, Geslin P, Bingen E. Emergence in France of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin. Antimicrob Agents Chemother 1999; 43: 1480-1483.